Company intelligence / Profile preview

Arrow Generics

Castleford, West Yorkshire, United Kingdom

Ownership: Private
Employees: ~1000
Development stage: Other

Overview

Arrow Generics, a prominent player in the global generic pharmaceutical market, has successfully demonstrated bioequivalence for a portfolio of over 100 molecules. The company is particularly noted for its commercialization of the first authorized generic of atorvastatin (Lipitor) and its involvement in significant patent litigation that established the 'Arrow declaration' legal precedent.

Therapeutic areas: EndocrinologyCardiovascularNeurologyInfectious DiseasesPsychiatryOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Pfizer (Authorized generic Lipitor agreement)Lundbeck (Citalopram patent settlement)

Beyond the preview

Go deeper on Arrow Generics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arrow Generics.

Explore the full profile